- Bird Flu Virus in Canadian Teen Shows Mutations That Could Help It Spread Among Humans
- Flu, COVID Vaccination Rates Remain Low as Winter Nears
- ’10 Americas:’ Health Disparities Mean Life Expectancy Varies Across U.S.
- Short-Term Hormone Therapy for Menopause Won’t Harm Women’s Brains
- Could a Vitamin Be Effective Treatment for COPD?
- Woman Receives World’s First Robotic Double-Lung Transplant
- Flavored Vapes Behind Big Surge in U.S. E-Cigarette Sales
- Reading Beyond Headline Rare For Most on Social Media, Study Finds
- Meds Like Ozempic Are Causing Folks to Waste More Food
- Fibroids, Endometriosis Linked to Shorter Life Spans
Suppository Eases Vaginal Dryness in Small Study
For postmenopausal women, suppositories containing the hormone DHEA may reduce vaginal dryness, discomfort and pain during sex without raising overall estrogen levels, researchers report.
DHEA is an anti-aging hormone produced by both women and men. In supplement form, it is used to improve thinking skills in older people. But DHEA is also a hormonal precursor of estrogen and testosterone, so some women who have low levels of certain hormones take it to improve well-being and sexuality, according to the U.S. National Library of Medicine.
“Although this medication is considered ‘hormonal,’ the mechanism appears to be primarily local with minimal side effects beyond vaginal discharge from the suppository,” said Dr. JoAnn Pinkerton, executive director of the North American Menopause Society (NAMS).
Generally, without hormonal treatment after menopause, vaginal tissues shrink and produce less moisture, leading to discomfort during sex, and vaginal and urinary problems, according to background information in the study.
In this phase 3 clinical trial, 325 women who used the DHEA suppository daily saw significant improvements in vaginal dryness after 12 weeks, compared to 157 women using a placebo.
“Its action seems to be entirely within [vaginal] cells, and no significant amount of sex hormone gets released into the circulation,” Pinkerton said in a society news release.
“That means that intravaginal DHEA avoids the raised hormone levels that might stimulate breast tissue or the lining of the uterus, which are concerns for women at risk of estrogen-sensitive cancers, or cancer recurrence, in these organs,” she said.
The findings were published online Jan. 5 in the journal Menopause, a NAMS publication.
One woman’s health expert noted that DHEA may be a better option than estrogen treatments for some women.
“Intravaginal DHEA is a good alternative to estrogen creams in postmenopausal women with vaginal atrophy that manifests as vaginal dryness and pain with intercourse,” said Dr. Elizabeth Kavaler, an urology specialist at Lenox Hill Hospital in New York City.
“Intravaginal DHEA does not increase a woman’s exposure to the effects of estrogen that concern many women, like endometrial hyperplasia [thickening of the lining of the uterus that can raise the risk for cancer] and breast cancer risk,” Kavaler added.
More information
The U.S. Office on Women’s Health has more about menopause.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.